UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 156

Sortiert nach

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy

Drug resistance updates, 2016-11, Vol.29, p.90-106

2016

Volltextzugriff (PDF)

Pros and Cons of the Liposome Platform in Cancer Drug Targeting

Journal of liposome research, 2006-01, Vol.16 (3), p.175-183

2006

Volltextzugriff (PDF)

Preclinical evaluation of Promitil®, a radiation-responsive liposomal formulation of mitomycin C prodrug, in chemoradiotherapy

International journal of radiation oncology, biology, physics, 2016-11, Vol.96 (3), p.547-555

2016

Volltextzugriff (PDF)

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses

Nanomedicine, 2015-02, Vol.11 (2), p.259-262

2015

Volltextzugriff (PDF)

Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model

Biomolecules (Basel, Switzerland), 2023-08, Vol.13 (9), p.1309

2023

Volltextzugriff (PDF)

Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin

Clinical lymphoma & myeloma, 2008-02, Vol.8 (1), p.21-32

2008

Volltextzugriff (PDF)

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes

Anti-cancer drugs, 2015-03, Vol.26 (3), p.241-258

2015

Volltextzugriff (PDF)

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience

Frontiers in oncology, 2018-11, Vol.8, p.544

2018

Volltextzugriff (PDF)

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy

Frontiers in immunology, 2017-04, Vol.8, p.416-416

2017

Volltextzugriff (PDF)

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment

Seminars in cancer biology, 2021-01, Vol.68, p.175-185

2021

Volltextzugriff (PDF)

Reduced Toxicity and Superior Therapeutic Activity of a Mitomycin C Lipid-Based Prodrug Incorporated in Pegylated Liposomes

Clinical cancer research, 2006-03, Vol.12 (6), p.1913-1920

2006

Volltextzugriff (PDF)

Translational considerations in nanomedicine: The oncology perspective

Advanced drug delivery reviews, 2020, Vol.158, p.140-157

2020

Volltextzugriff (PDF)

Liposome circulation time and tumor targeting: implications for cancer chemotherapy

Advanced drug delivery reviews, 1995-09, Vol.16 (2), p.285-294

Gabizon, Alberto A.

1995

Volltextzugriff (PDF)

Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate

Journal of controlled release, 2018-02, Vol.271, p.139-148

2018

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

Cancer investigation, 2001, Vol.19 (4), p.424-436

Gabizon, Alberto A.

2001

Volltextzugriff (PDF)

Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients

Investigational new drugs, 2020-10, Vol.38 (5), p.1411-1420

2020

Volltextzugriff (PDF)

Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts

International journal of nanomedicine, 2018-01, Vol.13, p.7647-7656

2018

Volltextzugriff (PDF)

Pharmacokinetics of low molecular weight heparin in patients with malignant tumors

Anti-cancer drugs, 2015-01, Vol.26 (1), p.106-111

2015

Volltextzugriff (PDF)

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients

Cancer medicine (Malden, MA), 2015-10, Vol.4 (10), p.1472-1483

2015

Volltextzugriff (PDF)

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model

Nanotheranostics (Sydney, NSW), 2022, Vol.6 (4), p.451-464

2022

Volltextzugriff (PDF)

Abstract 4008: Pegylated liposomal alendronate: The impact of the drug cargo on carrier-induced immune modulation

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4008-4008

2016

Volltextzugriff (PDF)

Cardiac safety of liposomal anthracyclines

Seminars in oncology, 2004-12, Vol.31 (6 Suppl 13), p.161-181

2004

Volltextzugriff (PDF)

Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil® Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies

Cancer investigation, 2004, Vol.22 (5), p.663-669

2004

Volltextzugriff (PDF)

Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes

Cancer research (Chicago, Ill.), 1992-02, Vol.52 (4), p.891-896

GABIZON, A. A

1992

Volltextzugriff (PDF)

Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials

Seminars in oncology, 2004-12, Vol.31 (6 Suppl 13), p.53-90

2004

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(151)

Publikationsform

Sprache

Englisch
(155)
Japanisch
(29)

Erscheinungsjahr

n.n

Thema

Science & Technology
(105)
Life Sciences & Biomedicine
(96)
Humans
(72)
Female
(55)
Oncology
(52)
Animals
(49)
Liposomes
(49)
Pharmacology & Pharmacy
(47)
Biological And Medical Sciences
(41)
Medical Sciences
(40)
Mice
(35)
Doxorubicin - Administration & Dosage
(34)
Pharmacology. Drug Treatments
(34)
Chemotherapy
(31)
Antineoplastic Agents
(28)
Doxorubicin
(28)
Liposome
(27)
Chemistry
(22)
Antibiotics, Antineoplastic - Administration & Dosage
(21)
Middle Aged
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy

Pros and Cons of the Liposome Platform in Cancer Drug Targeting

Preclinical evaluation of Promitil®, a radiation-responsive liposomal formulation of mitomycin C prodrug, in chemoradiotherapy

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses

Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model

Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment

Reduced Toxicity and Superior Therapeutic Activity of a Mitomycin C Lipid-Based Prodrug Incorporated in Pegylated Liposomes

Translational considerations in nanomedicine: The oncology perspective

Liposome circulation time and tumor targeting: implications for cancer chemotherapy

Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate

Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients

Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts

Pharmacokinetics of low molecular weight heparin in patients with malignant tumors

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model

Abstract 4008: Pegylated liposomal alendronate: The impact of the drug cargo on carrier-induced immune modulation

Cardiac safety of liposomal anthracyclines

Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil® Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies

Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes

Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials

Suchergebnisse filtern